EUCTR2014-001013-81-PT进行中（未招募）1 期
Treatment of Bladder Pain Syndrome with Onabotulinum toxin A
Centro Hospitalar de São João, EPE0 个研究点目标入组 30 人开始时间: 2014年7月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Female patients aged between 20 and 60 years.
- •- Patients must have pain related to bladder filling, referred to bladder, urethra or perineum for at least 6 months with a score of at least 4 in a 0 (no pain) to 10 (maximum pain) visual analogue scale (VAS). Other urinary complaints such as frequency, urgency or nocturia may be present.
- •- For patients taking oral standard medication for their BPS/IC like PPS, amitriptyline or hydroxyzine must be discontinued at least 15 days prior to screening procedures and a treatment cannot be commenced during the study.
- •- For patients taking intravesical medication like heparinoids, PPS, chondrotin sulfate or DMSO medication must be discontinued at least 3 months prior to screening procedures and a treatment cannot be commenced during the study.
- •- Patients who have received Botulinum toxin type A or resiniferatoxin before, a period of at least 12 months must have elapsed prior to screening procedures. None of these two treatments can be concomitantly commenced during the study.
- •- If the patient is under analgesic medication (which includes paracetamol, non-steroidal anti-inflammatory drugs, gabapentin and pregabalin), she will be allowed at entry. However the dose must remain constant throughout the study duration. If the patient is off analgesic medication no de novo analgesic medication will be allowed during the study. However patients may receive analgesics once they withdraw the study.
- •- Patients must be able and be willing to use clean intermittent catheterization (CIC) at any time after study treatment, if it is determined to be necessary by the investigator.
- •- Anticoagulants, antiplatelet medications, or medications with anticoagulant effects (e.g., warfarin and other coumarinic derivatives, aspirin, clopidogrel, etc) will be prohibited prior to the administration of the study treatment within the following conditions stated in the guideline published by Douketis and colleagues (Douketis et al, 2012):
- •- Vitamin K antagonists will be interrupted for a minimum of 5 days before surgery.
- •- Antiplatelet/antiaggregant drug will be interrupted for a minimum of 7 days before surgery.
- •- These medications could be restarted the day following study treatment. If medically indicated, low molecular weight heparins (e.g. enoxaparin) will be permitted up to 24 hours prior to study drug treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnant or nursing patients
- •- Patients of childbearing potential that do not use adequate birth control methods (defined in Section 8.2.6)
- •- Patient has history or evidence of any pelvic or urological abnormalities including but not limited to the following:
- •- Current or frequent urinary tract infections (UTI) (> 2 in the last 6 months documented by urine culture) or is taking prophylactic antibiotics to prevent chronic UTI.
- •- History of bladder tumour with or without additional intravesical chemotherapy (mitomycin, BCG).
- •- History of previous pelvic radiotherapy, urinary tract tuberculosis, or exposure to ketamine.
- •- Current or previous non-investigated haematuria (patients with investigated haematuria may enter the study if urological/renal pathology has been ruled out to the satisfaction of the investigator).
- •- Surgery or bladder diseases that may impact bladder function including bladder stones, stress incontinence, endometriosis, uterine prolapse, rectocele, cystocele or any pelvic surgery.
- •- Estimated creatinine clearance rate (eCCr) lower than 30 ml/min, calculated by the Cockcroft-Gault formula:
- •eCCr=((140-Age in years)×Mass (in kilograms))/(72×serum creatinine (in mg/dl))[×0.85 if female]
- •- Cardiac, pulmonary and hematologic conditions or other diseases that may preclude a safe general anaesthesia, in the opinion of the investigator.
- •- Patients at high risk of thrombotic events for whom suspension of antiplatelet or anticoagulant treatment puts patients’ safety at risk.
- •- Patient with a post void residual (PVR) urine volume of > 100 ml at screening.
- •- History of neuromuscular transmission disorders including, but not limited to myasthenia gravis and Eaton Lambert Syndrome
- •- Patients with peripheral motor neuropathic diseases including but not limited to amyotrophic lateral sclerosis.
- •- Allergy to OnabotA or any of the study treatments' componentes.
- •- Administration of OnabotA for other reasons than BPS/IC in the previous 12 weeks.
研究者
相似试验
进行中（未招募）
不适用
Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial CystitisPainful bladder syndrome / interstitial cystitis (PBS/IC)MedDRA version: 1Level: LLTClassification code 10005063Term: <Manually entered code. Term in E.1.1>EUCTR2008-001501-42-FIJukka Sairanen
Unknown
2 期
Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' LesionsInterstitial CystitisNCT01437579Moscow State University of Medicine and Dentistry60
招募中
3 期
Overactive bladder treatment by Intravaginal injection of botulinum toxin AIRCT20211203053261N1Shahid Beheshti University of Medical Sciences50
进行中（未招募）
1 期
Treatment with Botox in patients with urinary incontinence (accidental loss of urine) due to neurogenic detrusor overactivity (bladder problems resulting from disease or damage to the nervous systemrinary incontinence due to neurogenic detrusor overactivityMedDRA version: 18.0Level: PTClassification code 10029279Term: Neurogenic bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2014-004641-27-BEZLeuven30
招募中
4 期
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive BladderOveractive BladderNCT04020510Walter Reed National Military Medical Center184